Free shipping on all orders over $ 500

WY 14643 (Pirinixic Acid)

Cat. No. M1880
WY 14643 (Pirinixic Acid) Structure
Synonym:

Pirinixic Acid; NSC 310038

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mg USD 40  USD40 In stock
50mg USD 80  USD80 In stock
100mg USD 100  USD100 In stock
200mg USD 150  USD150 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

WY 14643 is a highly potent PPARα agonist with EC50 values of 0.63, 32 and > 100 μM at PPARα, PPARγ and PPARδ respectively. PPARα is a subtype of PPAR, which controls the expression of genes involved in cardiac fatty acid utilization. Activated PPARs act as transcription factors to increase expression of specific genes within cells. In vitro, WY 14643 (Pirinixic Acid) inhibits NF-κB transcriptional activity and decreases the inflammatory response. And Pirinixic Acid inhibits the proliferation of trophoblast cells in vivo. MCD diet-induced fibrosing steatohepatitis can be reversed by treatment with WY-14643. WY 14643 may increase the progesterone secretion. Effects of WY-14643 on metabolism of human trophoblast cells are different from those of clofibric acid.

Product Citations
Customer Product Validations & Biological Datas
Source J Mol Neurosci (2016). Figure 6. WY 14643
Method western blot
Cell Lines Ik-B
Concentrations 10, 100 μM
Incubation Time 24 h
Results Decreasing of phosphorylated IkB and increasing of total IkB protein level were also observed following WY- 14643 treatment (Fig. 6), indicating that the phosphorylation, ubiquitination, and degradation of IkB induced by LPS was inhibited by WY-14643.
Source J Mol Neurosci (2016). Figure 1. WY 14643
Method real-time PCR
Cell Lines Ik-B
Concentrations 10, 100 μM
Incubation Time 24 h
Results In PPAR-α-specific siRNA-transfected cells, WY-14643 was unable to induce the expression of PPAR-α
Protocol (for reference only)
Cell Experiment
Cell lines U937 cells
Preparation method Adhesion Assay.
ECs were grown to confluence in 96-well plates, pretreated with PPARα activators for 24 hours, and stimulated with TNF-α for 8 hours, then adhesion assays were performed.19 Briefly, U937 cells were labeled with 2',7'-bis(2-carboxy)-fluorescein acetoxymethyl ester (Molecular Probes) and then added, under rolling conditions (63 rpm, 23°C, 15 minutes), to a rinsed EC monolayer (2×106 cells/mL) in RPMI medium/10% FCS/1 mmol/L CaCl2. Nonadherent cells were removed by inverting the plate under rotation (20 minutes). After solubilization of well contents, fluorescence intensity was measured in a microtiter plate fluorimeter (Pandex, FCA). A standard curve using dilutions of labeled U937 cells was determined, and results were expressed as cells/cm2.
Concentrations 250 µmol/L
Incubation time 24 h
Animal Experiment
Animal models Homozygous obese (Ob) Zucker rats model of partial (~70%) hepatic warm ischemia
Formulation -
Dosages 10 mg/kg
Administration intravenously
Chemical Information
Molecular Weight 323.8
Formula C14H14ClN3O2S
CAS Number 50892-23-4
Solubility (25°C) DMSO 65 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Pantazi E, et al. Biomed Res Int. PPARα Agonist WY-14643 Induces SIRT1 Activity in Rat Fatty Liver Ischemia-Reperfusion Injury.

[2] Marx N, et al. Circulation. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells.

Related PPAR Products
DSO-5a

DSO-5a is a potent, selective, orally active BB3 agonist.

Carfloglitazar sodium

Carfloglitazar sodium is a dual agonist of the pan peroxisome proliferator-activated receptor (PPARα/γ) with EC50 values of 1.2, 0.08, and 1.7 μM for PPARα, PPARγ, and PPARδ, respectively.It can be used in studies related to nonalcoholic steatohepatitis (NASH).

Seladelpar

Seladelpar is a potent, orally active, specific PPAR-δ agonist with an EC50 of 2 nM.

4'-O-Methylhonokiol

4-O-Methyl honokiol is a natural neolignan isolated from Magnolia officinalis, acts as a PPARγ agonist, and inhibtis NF-κB activity, used for cancer and inflammation research.

3-Phenyl-2-propen-1-ol

trans-Cinnamyl alcohol is a trans-isomer of Cinnamyl alcohol.

  Catalog
Abmole Inhibitor Catalog




Keywords: WY 14643 (Pirinixic Acid), Pirinixic Acid; NSC 310038 supplier, PPAR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.